# ORIX USA Growth Capital

> ORIX USA's Growth Capital business provides financing to technology and healthcare companies. Its own strategy page describes debt structures and equity co-investments, including senior and junior lending. On October 21, 2026, the business confirmed participation in Kevel's $52M financing alongside Fulcrum Equity Partners, dunnhumby Ventures and Iberis Capital. Managing director Blake Zhang's statement emphasizes increasing complexity across onsite, offsite and in-store retail media. The deal announcement does not disclose ORIX's allocation or the financing's equity/debt split. This profile represents the ORIX USA business, not a separately announced fund vehicle.

## Profile

- **Stage-based planning range:** $100K–$1M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** N/A
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** Growth
- **Last verified:** 2026-10-24

## Links

- [Website](https://www.orix.com/private-credit/growth-capital/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 24, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/orix-usa-growth-capital